

ABSTRACT

The present invention provides a mesothelioma
therapeutic agent containing an interleukin-6 (IL-6)
5 antagonist such as antibody to IL-6 receptor (IL-6R), and
a mesothelioma cell growth inhibitor containing an IL-6
antagonist such as antibody to IL-6R.